Santamaría Amparo, Antón-Maldonado Cristina, Sánchez-Quiñones Beatriz, Ibarra Vega Nataly, González Pedro, Carrasco Rafael
Hybrid Hematology Department, University Hospital Vinalopó, 03293 Alicante, Spain.
Fundación Para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46020 Valencia, Spain.
J Clin Med. 2025 Apr 27;14(9):3023. doi: 10.3390/jcm14093023.
The aim of this study was to evaluate, for the first time, the feasibility of implementing LOLA, a speech-AI-driven conversational assistant, in monitoring and managing OAT for patients with non-valvular atrial fibrillation (AF). In 2023, we conducted a pilot prospective observational study of patients with non-valvular atrial fibrillation (AF) and TAO. All patients received a first-contact call from LOLATAO and then monthly calls following a protocol predefined by haematologists. At the end of the study, a satisfaction questionnaire was carried out. Of the fifty patients, the mean age was 75 years, and 33% were women. One-third of the patients (n = 16) were receiving antivitamin K treatment, and two-thirds (33) DOACs. A total of 579 calls were made with a median follow-up of 278 days. LOLATAO had high rates of acceptability (85%), adherence (90%), and satisfaction (>95%). A total of 42% of the patients reported at least one missed dose within the last month, and 18% reported having a scheduled intervention requiring bridging therapy. In patients with AVKs, 94% (n = 15) reported being unaware of their TRT at least once, and 75% (n = 12) of patients reported having a TRT < 65%. Those patients in whom the TRT was <65% were switched to DOACs. LOLATAO saved a total of 10 h per month for haematologists during follow-up. This study suggests that LOLATAO can be a helpful tool in the management of chronic follow-up of patients with AF and undergoing OAT, reducing the burden of care and with high rates of acceptance and satisfaction by patients.
本研究的目的是首次评估实施LOLA（一种语音人工智能驱动的对话助手）在监测和管理非瓣膜性心房颤动（AF）患者口服抗凝治疗（OAT）方面的可行性。2023年，我们对非瓣膜性心房颤动（AF）和血栓形成倾向（TAO）患者进行了一项前瞻性试点观察研究。所有患者均接到来自LOLA TAO的首次联系电话，随后按照血液科医生预先定义的方案每月接到电话。在研究结束时，进行了满意度问卷调查。在50名患者中，平均年龄为75岁，33%为女性。三分之一的患者（n = 16）正在接受维生素K拮抗剂治疗，三分之二（33名）正在接受直接口服抗凝剂（DOACs）治疗。共拨打了579个电话，中位随访时间为278天。LOLA TAO具有较高的可接受率（85%）、依从率（90%）和满意度（>95%）。共有42%的患者报告在过去一个月内至少漏服一剂，18%的患者报告有需要桥接治疗的预定干预措施。在服用维生素K拮抗剂的患者中，94%（n = 15）报告至少有一次不知道自己的治疗范围时间（TRT），75%（n = 12）的患者报告其治疗范围时间<65%。那些治疗范围时间<65%的患者被换用直接口服抗凝剂。在随访期间，LOLA TAO每月为血液科医生总共节省了10小时。这项研究表明，LOLA TAO可以成为管理AF患者和接受OAT患者慢性随访的有用工具，减轻护理负担，患者接受率和满意度较高。
